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Patients with cystic ﬁbrosis (CF) have several risk factors for Clostridium difficile colonization such as frequent hospitalization and exposure to
a broad array of antibiotics utilized for the control, eradication, and prophylaxis of respiratory pathogens. However, despite this high rate of
colonization, the occurrence of C. difficile infection (CDI) in CF is rare. We report three children with CF who presented with severe community-
associated CDI. All three children had complicated courses and one died. These children were in good health without signiﬁcant morbidities, and
were not frequently hospitalized nor did they receive frequent antibiotic courses. The occurrence of 3 severe cases within a 15-month period
prompted us to report these cases and review the literature in regard to CDI. We reviewed the CF GI tract as possible risk factors for a high rate of
C. difficile colonization in individuals with CF. Since a high percentage of individuals with CF are on gastric acid blocking agents, we also focused
on gastric acid suppression as a potential risk factor for CDI.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Acid blockers; Diarrhea; Clostridium difficile; Cystic ﬁbrosis; Proton pump inhibitors1. Introduction
Clostridium difficile is the most common cause of infectious
nosocomial diarrhea, both in normal and immunocompromised
hosts. Several risk factors have been linked to C. difficile
infection (CDI) including prolonged hospital stay, exposure
to antibiotics (especially multiple antibiotics with prolonged
duration), existence of inflammatory bowel disease, gastroin-
testinal procedures, and immunocompromised host [1]. The
incidence of CDI has increased over the past decade. Similarly,
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,lishedstrain have also increased [1].
In healthy adults, the asymptomatic carriage rate of toxigenic
and non-toxigenic C. difficile has been found to be 0–17.5% [2].
Studies have shown an even higher (up to 50%) rate of colonic
colonization with C. difficile in individuals with cystic fibrosis
(CF) [3]. Patients with CF have several risk factors for C. difficile
colonization such as frequent hospitalization and exposure to a
broad array of antibiotics utilized for the control, eradication, and
prophylaxis of respiratory pathogens. However, despite this high
rate of colonization, the occurrence of complicated CDI in CF is
rare [3].
Studies suggest that gastric acid suppression is associated
with an increased incidence of CDI in the non-CF population in
both community and hospital settings [4–10]. The majority of
patients with CF in the US are on gastric acid suppressive
treatments mainly due to the high rate of gastroesophageal
reflux (GER) in individuals with CF. In addition, since there isby Elsevier B.V. All rights reserved.
Fig. 1. Case #3, prior to total colectomy. Diffuse colonic wall edema and
dilation of colon associated with toxic megacolon.
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improve the efficacy of the pancreatic enzymes [11], it has
been a common practice to start acid blockers for patients with
symptoms of maldigestion despite maximum dose of pancreatic
enzyme replacement therapy (PERT). Per the 2011 CF Foundation
Patient Registry Report (CFFPR), 70.1% of individuals with CF in
the United States were on gastric acid blocker agents, and in some
centers, the rate is as high as 100% [12].
Several reports describe severe complicated CDI in CF
patients with and without lung transplantation [3,13–15]. These
cases occurred in the hospital setting and all had a history of
recent antibiotic exposure. Here we report three cases with
severe community-associated CDI as defined by the Society of
Healthcare Epidemiology of America (SHEA) and Infectious
Diseases Society of America (IDSA) [16]. All three children
had complicated courses and one died. These children were
in good health without significant morbidities, and were not
frequently hospitalized nor did they receive frequent antibiotic
courses. Only one child had received a recent 1-week course of
antibiotics before developing CDI and this was a short course
of amoxicillin completed three weeks prior. Therefore, in this
article, we reviewed CDI and associated risk factors and focused
on CF gastrointestinal (GI) tract and gastric acid blocking agents
as potential risk factors.
2. Cases
2.1. Case 1
A 7 1/2 month-old male with CF was admitted to the
hospital with vomiting, non-bloody diarrhea, fever, and abdom-
inal distention. The stool study was positive for C. difficile A/B
toxin. Over the next 2 days, his condition worsened despite
antibiotic (metronidazole) treatment and he remained hemody-
namically unstable. The CT of the abdomen showed thickening
of the colon and small bowel wall, and extensive dilation of colon
with significant ascites. He was taken to the OR for exploratory
laparotomy and possible colon resection; however, he suddenly
deteriorated and developed irreversible cardiorespiratory failure
requiring extracorporeal membrane oxygenation (ECMO) treat-
ment. A second laparotomy showed retroperitoneal hemorrhage,
and 2 days later, the support was withdrawn.
He was born at 35 weeks of gestational age and diagnosed
via CF newborn screening. He had been hospitalized twice for
the treatment of malnutrition and eradication of Pseudomonas
aeruginosa (last hospitalization was 4 months prior). He did
not have a history of recent antibiotic use. His recent respi-
ratory cultures were positive for Haemophilus influenza and
Haemophilus parainfluenzae. He had been receiving lansoprazole
15 mg/day for four months for the treatment of clinical GER.
2.2. Case 2
An 8 year-old male with CF presented with septic shock.
His symptoms started 2 days prior to hospital admission and
included vomiting and non-diarrhea followed by confusion and
lethargy. He was intubated in the ambulance en route andadmitted to the intensive care unit. The stool became bloody
and was positive for C. difficile A/B toxin. Metronidazole
and vancomycin (for MRSA) were started. The abdominal
CT showed significant dilation of distal small bowel and
ascending colon with diffuse wall thickening of total colonic
wall with significant ascites. The patient remained intubated for
4 days and was discharged home after 17 days of hospital stay.
He was diagnosed with CF at the age of four months after his
older sibling was diagnosed with CF. His nutritional status was at
goal (BMI 60th percentile) with well-preserved lung function
(FEV1 110% predicted). He had not been treated with antibiotics
over the past several months, although his respiratory cultures
had been positive for MRSA intermittently. He had been on
esomeprazole 20 mg twice a day for N5 years due to severe GER.
2.3. Case 3
A 14 year-old girl with CF developed sudden onset fever,
diarrhea, and abdominal pain. She was admitted to the hospital
due to persistent fever and bloody diarrhea. Stool study was
positive for C. difficile toxin A/B, and she was started on
IV metronidazole. CT of the abdomen showed diffuse wall
thickening and significant dilation of the colon consistent with
toxic megacolon (Fig. 1). On the third day of admission,
abdominal distention and bloody diarrhea persisted and oral
vancomycin was added. On the 6th day of admission, due to
persistent abdominal distention and hemodynamic instability
and concern for impending colonic perforation, she was taken
to the OR and a total colectomy and ileostomy were performed.
On gross pathologic examination, pseudomembranes were easily
appreciated. Sections of the colon showed a denuded surface
epithelium, a dense infiltrate of neutrophils within superficial
lamina propria, and pseudomembrane formation adherent
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mucupurulent exudate that formed eruptions resembling a
volcano (Fig. 2A, B). She was discharged home 12 days later
on oral feedings.
She was diagnosed with CF at age of 6 months. She had
never been hospitalized except at the time of diagnosis, and had
been in good health associated with a BMI at the 50th percentile
and a FEV1 of 120% predicted. Although her respiratory cultures
have been repeatedly positive for MRSA, she did not have
a history of inpatient or outpatient antibiotic use except treatment
with amoxicillin for one week before a dental procedure three
weeks prior to her presentation. Table 1 summarizes the
characteristics of the cases.3. Discussion
We report three children with CF who presented with
community-associated CDI with severe complicated courses.
Community-associated CDI is defined by SHEA and IDSA as
“disease in persons with no overnight stay in an inpatient
healthcare facility in at least the 12 weeks prior to symptom
onset” [16]. None of our patients were hospitalized within the
12 weeks prior to symptom onset although one was hospitalized
4 months prior. However, the source of community-associated
CDI is poorly understood [17] and they may have acquired the
pathogen during outpatient clinic visits. Reports describe severe
CDI in the hospital setting in CF patients who have undergone
lung transplantation; however, complicated community-associated
CDI has not been reported in relatively healthy individuals with
CF. The occurrence of 3 severe cases within a 15-month period
prompted us to report these cases and review the literature in
regard to CDI. We reviewed the CF GI tract as a possible risk
factor for a high rate of C. difficile colonization in individuals with
CF. Since a high percentage of individuals with CF are on gastric
acid blocking agents, we also focused on gastric acid suppression
as a potential risk factor for CDI.3.1. CF and CDI
3.1.1. Is CF a risk factor for C. difficile colonization and CDI?
In the hospital setting, up to 50% of patients with CF may
acquire C. difficile [3,18]. Patients with CF have several riskFig. 2. The post-operative pathology sample shows a thick pseudomembrane formed
colonic mucosa (A) and exudate erupting from areas of mucosal erosion resemblingfactors associated with C. difficile colonization such as frequent
hospitalizations and being exposed to a broad array of antibiotics
utilized for the control, eradication, and prophylaxis of airway
pathogens. Other risk factors for C. difficile infection common in
the CF population include gastrostomy and GI tract surgery [19].
One of the oldest studies in a hospital setting showed a high
asymptomatic (32%) carriage rate of toxigenic strains of
C. difficile in patients with CF who were on systemic antibiotics
[14]. The rate was 17% in non-CF control subjects who were
on antibiotics. However, despite high rates of colonization, the
occurrence of complicated CDI in CF is rare. Reports of severe
CDI in CF are usually related to patients who have undergone
lung transplantation. A study by Theunissen et al. showed that
patients with CF who were lung transplant recipients had a higher
risk of developing CDI [3]. Similarly, Rosen et al. reported an
incidence of 5.4% CDI in children following lung transplantation
in a 6 year period [15]. More recently, Egressy et al. reported 10
cases of recurrent CDI in CF who had undergone lung
transplantation over a 17-year period [13].
There are no case reports of complicated community-associated
CDI in patients with CF without recent antibiotic exposure. All of
our children were in good health, developed symptoms at home,
and they did not have a history of antibiotic use except case 3.3.1.2. Is the abnormal CF gut a risk factor for CDI?
Pancreatic insufficiency and related malabsorption of nutrients
are the major GI pathologies in CF. However, GI mucosal
barriers, intestinal function, and microbiota are not well studied.
The CFTR-deficient mouse serves as a model of the GI features
of CF. It has recently been reported that these mice have in-
flammation of the small intestine with infiltration of mast cells
and neutrophils, as well as upregulation of several inflammation-
associated genes [20]. DeLisle and his colleagues showed that
CF mice had impaired mucosal barrier function and bacterial
overgrowth [21]. In addition, the circular smoothmuscle fromCF
mice has a profound lack of activity and was non-responsive
to cholinergic stimulation causing impaired small intestinal
transit [22]. By using capsule endoscopy technique, Werlin et
al. demonstrated varying degrees of diffuse areas of inflam-
matory findings in the small bowel of adults with CF in 63%
of their study population [23]. This included frank ulcerations
in conjunction with high levels of fecal calprotectin levelsby neutrophils, epithelial debris, red blood cells, fibrin, and mucus adheres to the
lava erupting from a volcano (B).
Table 1
Summary of characteristics of three pediatric patients who presented with severe community-acquired community associated CDAD.
Case Age Gender Genotype Nutrition at
admission
Best
FEV1
Medications Presentation Antibiotic
exposure
Imaging Outcome
1 7.5 m M Homo
Del F508
Weight for
length at
30% p
N/A PPI 7.5 mg BID
PERT
CF vitamins
Diarrhea
Abdominal
distension
No Dilation of small
bowel and colon
Colon wall
thickening
Ascites
ECMO
Died
2 8 y M Homo
Del F508
BMI at
60% p
110 PPI 20 mg BID
Dornase alfa
PERT
CF vitamins
Septic shock
Respiratory failure
No Dilation of small
bowel and colon
Diffuse colon wall
thickening
Ascites
Cardiorespiratory
failure
PICU stay for
2 weeks
Full recovery
3 14 y F Homo
Del F508
BMI at
46% p
120 Dornase alfa
PERT
CF vitamins
Bloody diarrhea
Abdominal distension
Amoxicillin 3
weeks prior
Diffuse colon
dilation and colon
wall thickening
Ascites
Total colonic
resection
with enterostomy
Abbreviations: CDAD — C. difficile associated diarrhea, ECMO — extracorporeal membrane oxygenation therapy, PPI — proton pump inhibitor, PERT —
pancreatic enzyme replacement therapy.
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gut” associated with chronic intestinal inflammation, bacterial
overgrowth, and slow intestinal transit time may be a risk
factor for high rates of C. difficile colonization in CF. Despite
this significant rate of colonization, it is unusual for a healthy
CF patient to develop severe complicated CDI with no readily
discernible risk factors.
3.2. Gastric acid suppression
3.2.1. Gastric acid suppression and CDI
As gastric acid is effective in killingC. difficile and neutralizing
its toxin, there is a ready rationale for the results of studies that
have demonstrated a correlation between gastric acid suppression
and an increased incidence of CDI in both community and
hospital settings [4,5,9,24]. A large case–control study evaluated
the risk of CDI associated with gastric acid suppression. Both
H2 receptor agonists and proton pump inhibitor (PPI) use were
associated with an increased risk of community-associated CDI,
although the relative risk was greater with PPI's [7].
Two recent meta-analyses also confirm that PPI treatment
confers a significantly increased risk of CDI [25,26]. The first
report analyzed 23 studies, both hospital and community based,
and found a 65% increase in the incidence of CDI among
patients on PPI's [26]. The analysis included 300,000 patients,
and the majority of subjects were adults, although children
were represented in 4 studies. The second report included 42
observational studies with total of 313,000 participants. A pooled
analysis of 39 studies showed a statistically significant associa-
tion between PPI use and risk of developing CDI [25].
3.2.2. Gastric acid suppression and CF
The majority of patients with CF in the United States are
on gastric acid suppression due to two reasons. First, patients
with CF are at high risk of GER due to a variety of reasons such
as chronic cough, delayed gastric emptying, and high-fat diet
[27]. Second, although pancreatic enzyme replacement therapy
(PERT) significantly improves fat absorption, complete isgenerally not achieved in patients with CF. Pancreatic enzyme
supplements are enteric coated to prevent breakdown in gastric
acid. When they reach the increased pH in the duodenum, the
enteric coating dissolves. In people with CF, there is a decreased
or absence of pancreatic HCO3 secretion [28], and thus a lower
pH in the duodenum; therefore, taking a gastric acid blocker will
increase the pH in the duodenum and thus potentially improving
the effectiveness of PERT. There have been a number of small
clinical trials evaluating the effect of gastric acid suppression for
enzyme boosting in people with CF but the results have been
inconclusive [29,30]. A recent Cochrane review concluded that
there is not sufficient evidence to recommend this practice [31].
Despite the lack of conclusive evidence, it has become a common
practice in the United States to start acid blockers for patients with
symptoms of maldigestion despite maximum doses of PERT.
In the non-CF population, acid suppression is a potential risk
factor for CDI in the hospital and community setting. Although
increase use of acid-suppressing drugs in CF may contribute
to the high rate of C. difficile colonization in this population,
it does not allow the conclusion that CF patients on gastric acid
suppression are at higher risk for CDI as other factors may
be necessary for these patients to develop disease. Based on
Johnson et al's “three-hit disease” theory for the pathogenesis
of CDI [32], the first hit is exposure to antimicrobials and the
second hit is exposure to toxigenic C. difficile. Afterwards, either
the patient will be a carrier or will develop CDI. Interestingly, the
literature is not clear whether an asymptomatic carrier is at risk
for CDI [32]. The third hit that is necessary for CDI to occur
include host related factors and pathogen related factors. Our
third patient had antibiotic exposure, although brief, and our first
case may have colonized with C. difficile during his previous
hospital stay. The host/pathogen related factors could be that
either these patients were infected with virulent strains like in the
third case or neutralization of gastric acid was the host related
factor for the first 2 cases. Yet several questions remain: Infection
with more virulent strains of C. difficile such as PCR Ribotype
027 may cause severe CDI even in the community. However,
molecular typing of early studies showed that even the most
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suggesting that factors in addition to virulence are necessary for
CDI to occur [32].
3.2.3. Probiotics
Probiotics contain a sufficient number of viable microorgan-
isms to alter the microflora and have the potential for beneficial
health effects. They can be taken as an oral supplement or product
like yogurt. Probiotic microorganisms are typically members
of the genera Lactobacillus, Bifidobacterium, or Streptococcus.
These bacteria produce lactic acid and they are able to prevail
over potential pathogenic microorganisms in the human gastro-
intestinal tract. These microbes may generate byproducts that
have a beneficial regulatory effect on the biological functions of
the host by functioning as immune modulators [33].
Although it is the clinical practice at our institution to place all
CF patients on Lactobacillus throughout a course of antibiotics,
it is not known if such therapy is effective in preventing CDI.
Administration of currently available probiotics is not recom-
mended to prevent primary C. difficile infection, as there are
limited data to support this approach and there is a potential risk of
bloodstream infection [16]. However, an animal study showed that
mice were protected against infection by Listeria monocytogenesis
when they were orally fed a strain of Lactobacillus salivarius that
produce bacteriocin APB118 [34].
4. Limitations
In our hospital, we use a molecular assay for the detection of
C. difficile in stool (illumigene ®) which does not differentiate
toxin A from toxin B strains. We also do not know whether our
patients were infected with a virulent strain responsible for the
severe disease courses.
5. Conclusion
Community-associated severe CDI can occur in individuals
with CF without antibiotic exposure. Therefore, a high index
of suspicion is warranted in children presenting with abdominal
symptoms consistent with possible CDI. Furthermore, treatment
with PPI's may be a risk factor for C. difficile colonization and
CDI in people with CF and therefore should be used judiciously
in this patient population with multiple risk factors for CDI.
Future clinical trials should evaluate risk factors for CDI in
people with CF including whether gastric acid suppression is a
significant risk factor.
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